Search Results - "Burstein, H J"

Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019.

Authors: Burstein, H J Curigliano, G Loibl, S et al.

Source: Annals of Oncology. Oct2019, Vol. 30 Issue 10, p1541-1557. 17p. 8 Charts, 1 Graph.

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

Authors: Curigliano, G. Burstein, H. J. Winer, E. P. et al.

Source: Annals of Oncology. Aug2017, Vol. 28 Issue 8, p1700-1712. 13p. 5 Charts.

Duration of adjuvant trastuzumab: might less be more?

Authors: Filho, O Metzger Burstein, H J

Source: Annals of Oncology. Dec2018, Vol. 29 Issue 12, p2273-2274. 2p. 1 Chart.

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

Authors: Curigliano, G Burstein, H J Winer, E P. et al.

Source: Annals of Oncology. Jul2019, Vol. 30 Issue 7, p1181-1181. 1p.

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

Authors: Curigliano, G Burstein, H J Winer, E P et al.

Source: Annals of Oncology. Oct2018, Vol. 29 Issue 10, p2153-2153. 1p.

Experts' perspectives on the role of medical marijuana in oncology: A semistructured interview study.

Authors: Braun, I M Meyer, F L Gagne, J J et al.

Source: Psycho-Oncology. Jan2017, Vol. 26 Issue 1, pN.PAG-N.PAG. 1p.

Subjects: Hydrocarbons, Nausea, Medical quality control, Medical societies, Oncology, Tumors, Medical marijuana, Therapeutics, Prevention

Geographic Terms: United States

This result is not displayed to guests.
Login for full access.

CMF revisited in the 21st century.

Authors: Munzone, E. Curigliano, G. Burstein, H. J. et al.

Source: Annals of Oncology. Feb2012, Vol. 23 Issue 2, p305-311. 7p. 3 Charts.

Third consensus on medical treatment of metastatic breast cancer.

Authors: Beslija, S. Bonneterre, J. Burstein, H. J. et al.

Source: Annals of Oncology. Nov2009, Vol. 20 Issue 11, p1771-1785. 15p. 1 Chart.

A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma.

Authors: Mayer, E L DeMichele, A Rugo, H S et al.

Source: Annals of Oncology. Sep2019, Vol. 30 Issue 9, p1514-1520. 7p. 4 Charts, 1 Graph.

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.

Authors: Francis, P. A. Pagani, O. Fleming, G. F. et al.

Source: New England Journal of Medicine. 7/12/2018, Vol. 379 Issue 2, p122-137. 16p.

Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer.

Authors: Olson, E. M. Lin, N. U. DiPiro, P. J. et al.

Source: Annals of Oncology. Jan2012, Vol. 23 Issue 1, p93-97. 5p.

Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer.

Authors: Wu, Y. Amonkar, M. M. Sherrill, B. H. et al.

Source: Annals of Oncology. Dec2011, Vol. 22 Issue 12, p2582-2590. 9p.

SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer.

Authors: Mayer, E. L. Dhakil, S. Patel, T. et al.

Source: Annals of Oncology. Dec2010, Vol. 21 Issue 12, p2370-2376. 7p. 1 Diagram, 4 Charts, 1 Graph.

Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens.

Authors: Blackwell, K. L. Pegram, M. D. Tan-Chiu, E. et al.

Source: Annals of Oncology. Jun2009, Vol. 20 Issue 6, p1026-1031. 6p. 4 Charts, 2 Graphs.

Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer.

Authors: Wu, Y Amonkar, M M Sherrill, B H et al.

Source: Annals of Oncology. Jun2019, Vol. 30 Issue 6, p1019-1019. 1p.

SACI-IO HR+: a randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.

Authors: Garrido-Castro AC Kim SE Li T et al.

Source: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2026 Jun 20. Date of Electronic Publication: 2026 Jun 20.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE

Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer.

Authors: Francis PA Pagani O Fleming GF et al.

Corporate Authors: Francis PA Pagani O Fleming GF et al.

Source: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2026 Jun 01. Date of Electronic Publication: 2026 Jun 01.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE

Corrigendum to 'Long-term outcomes with adjuvant CDK4/6 inhibitors: who benefits most?': [Annals of Oncology. Volume 37, Issue 2, February 2026, Pages 133-135].

Authors: O'Meara TA Burstein HJ

Source: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2026 Apr 07. Date of Electronic Publication: 2026 Apr 07.

Publication Type: Published Erratum

Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE

Long-term outcomes with adjuvant CDK4/6 inhibitors: who benefits most?

Authors: O'Meara TA Burstein HJ

Source: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2026 Feb; Vol. 37 (2), pp. 133-135. Date of Electronic Publication: 2025 Oct 17.

Publication Type: Editorial

Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE; In Process